Intracellular signalling by NO/cGMP/cGMP-dependent protein kinase type I (cGKI) regulates various physiological processes including smooth muscle contractility and platelet aggregation. An important mediator of this signalling cascade is the inositol 1,4,5-trisphosphate receptor I (IP 3 RI) associated protein cGMP kinase substrate (IRAG). This protein forms a trimeric complex together with the cGMP kinase Iβ (cGKIβ) and the IP 3 RI. Targeted deletion of exon 12 of IRAG coding for the N-terminal part of the coiled-coil domain disrupted in vivo the IRAG-IP 3 RI interaction. The resulting IRAG ∆12/∆12 mice showed an increased mortality and a severely reduced gastrointestinal motility. The relaxation of hormone-contracted aortic and longitudinal colonic smooth muscle by cGMP was abolished in IRAG ∆12/∆12 mice, whereas cAMP-mediated relaxation was not altered. In contrast to WT mice, norepinephrine-induced increases in [Ca 2+ ] i were not reduced by cGMP in aortic smooth muscle cells from IRAG ∆12/∆12 mice. These data suggest, that IRAG is involved in the cGMP-dependent decrease of [Ca 2+ ] i in vivo and is essential for cGMP-dependent relaxation of hormone-induced vascular and colonic muscle contraction. However, cGMP-mediated relaxation of small intestinal smooth muscles was only partially affected in IRAG ∆12/∆12 mice suggesting tissue specific selectivity of cGKI mechanisms.
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In addition, IRAG is highly expressed in platelets. To study the effect of IRAG signalling in platelets, we analysed the aggregation of IRAG ∆12/∆12 platelets. Nitric oxide and the cGMP analogue 8-pCPT-cGMP did not inhibit the aggregation of IRAG ∆12/∆12 platelets in contrast to wild type platelets, whereas the shape change of platelets was not affected in both mutant and wild type platelets. Furthermore, tail bleeding was abbreviated in IRAG ∆12/∆12 mice suggesting a defect in the regulation of coagulation in vivo. Therefore, cGKI/IRAG/IP 3 RI signalling might be crucial for the NO/cGMP-dependent inhibition of platelet aggregation.
